Clinical Trial Update: Biomarker - Panitumumab Response With KRAS Wild Type MCC [NA]

View source ↗

Summary

Clinical-trial update evaluating whether KRAS wild-type status predicts response to panitumumab in metastatic colorectal cancer. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Vectibix (panitumumab)

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: Metastatic Colorectal Cancer | NA | Status: COMPLETED